HK1250927A1 - 用於配製肽蛋白酶體抑制劑的環糊精絡合法 - Google Patents

用於配製肽蛋白酶體抑制劑的環糊精絡合法

Info

Publication number
HK1250927A1
HK1250927A1 HK18110388.9A HK18110388A HK1250927A1 HK 1250927 A1 HK1250927 A1 HK 1250927A1 HK 18110388 A HK18110388 A HK 18110388A HK 1250927 A1 HK1250927 A1 HK 1250927A1
Authority
HK
Hong Kong
Prior art keywords
cylodextrin
proteasome inhibitors
peptide proteasome
complexation methods
formulating peptide
Prior art date
Application number
HK18110388.9A
Other languages
English (en)
Inventor
Evan Lewis
Peter Shwonek
Sean Dalziel
Mouhannad Jumaa
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1250927(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of HK1250927A1 publication Critical patent/HK1250927A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18110388.9A 2012-05-08 2018-08-14 用於配製肽蛋白酶體抑制劑的環糊精絡合法 HK1250927A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08
US201361777475P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
HK1250927A1 true HK1250927A1 (zh) 2019-01-18

Family

ID=48326170

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15108517.0A HK1207827A1 (zh) 2012-05-08 2015-09-01 用於配製肽蛋白酶體抑制劑的環糊精絡合法
HK18110388.9A HK1250927A1 (zh) 2012-05-08 2018-08-14 用於配製肽蛋白酶體抑制劑的環糊精絡合法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15108517.0A HK1207827A1 (zh) 2012-05-08 2015-09-01 用於配製肽蛋白酶體抑制劑的環糊精絡合法

Country Status (24)

Country Link
US (1) US10159746B2 (zh)
EP (2) EP4410374A2 (zh)
JP (1) JP6410264B2 (zh)
KR (5) KR20240119191A (zh)
CN (2) CN104411334A (zh)
AU (2) AU2013259573B2 (zh)
CA (1) CA2873044C (zh)
CL (1) CL2014003055A1 (zh)
DK (1) DK2662094T3 (zh)
EA (1) EA033614B1 (zh)
ES (1) ES2981576T3 (zh)
FI (1) FI2662094T3 (zh)
HK (2) HK1207827A1 (zh)
HR (1) HRP20240724T1 (zh)
HU (1) HUE066956T2 (zh)
IL (1) IL235553B (zh)
LT (1) LT2662094T (zh)
MX (2) MX364393B (zh)
PL (1) PL2662094T3 (zh)
PT (1) PT2662094T (zh)
RS (1) RS65647B1 (zh)
SG (2) SG11201407337QA (zh)
SI (1) SI2662094T1 (zh)
WO (1) WO2013169897A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009888A2 (en) 2013-07-19 2015-01-22 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
KR102655020B1 (ko) 2016-06-29 2024-04-04 케자르 라이프 사이언스 펩티드 에폭시케톤 면역프로테아좀 억제제의 결정질 염
EA201990157A1 (ru) 2016-06-29 2019-05-31 Кезар Лайф Сайнсиз Способ получения пептидного эпоксикетонового ингибитора иммунопротеасомы и его предшественников
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
TWI773706B (zh) * 2016-11-29 2022-08-11 瑞士商歐庫利斯公司 用於眼用活性藥物成分輸送的固體環糊精複合物之製備
AU2018263924B2 (en) * 2017-05-03 2024-07-04 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
EP3993807A1 (en) 2019-07-01 2022-05-11 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
CN110882221B (zh) * 2019-11-29 2021-06-29 健进制药有限公司 一种注射用卡非佐米冻干制剂的生产工艺
WO2022159319A2 (en) * 2021-01-19 2022-07-28 Mountain Valley Md Inc A porous aluminum nanoparticulate structure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
PT889056E (pt) 1997-07-01 2006-07-31 Pfizer Prod Inc Processo para produzir um,a ciclodextrina.
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
DE50110956D1 (de) 2000-10-12 2006-10-19 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
NZ548225A (en) * 2003-12-31 2012-12-21 Cydex Pharmaceuticals Inc Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
CN102174076A (zh) 2004-04-15 2011-09-07 普罗特奥里克斯公司 用于抑制蛋白酶体酶的化合物
DK1819353T3 (da) * 2004-12-07 2011-05-16 Proteolix Inc Sammensætning til proteasomhæmning
BRPI0618653A2 (pt) * 2005-11-15 2011-09-06 Baxter Int composições compreendendo inibidores da lipoxigenase e ciclodextrina
KR20150131405A (ko) * 2007-10-04 2015-11-24 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
KR20200106100A (ko) 2012-02-28 2020-09-10 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
HK1207827A1 (zh) 2016-02-12
JP6410264B2 (ja) 2018-10-24
SG10201609318UA (en) 2016-12-29
IL235553A0 (en) 2015-01-29
MX2014013552A (es) 2015-05-08
MX364393B (es) 2019-04-24
CA2873044A1 (en) 2013-11-14
KR20150008165A (ko) 2015-01-21
PT2662094T (pt) 2024-07-04
HRP20240724T1 (hr) 2024-08-30
DK2662094T3 (da) 2024-07-08
RS65647B1 (sr) 2024-07-31
CN104411334A (zh) 2015-03-11
EA201491994A1 (ru) 2015-04-30
EP4410374A2 (en) 2024-08-07
HUE066956T2 (hu) 2024-09-28
CN107693772A (zh) 2018-02-16
IL235553B (en) 2018-04-30
KR102054329B1 (ko) 2019-12-10
AU2013259573A1 (en) 2014-11-27
KR20220088949A (ko) 2022-06-28
PL2662094T3 (pl) 2024-08-05
JP2015516430A (ja) 2015-06-11
EP2662094A1 (en) 2013-11-13
AU2018200444A1 (en) 2018-02-08
US20150111838A1 (en) 2015-04-23
CA2873044C (en) 2021-01-26
ES2981576T3 (es) 2024-10-09
SI2662094T1 (sl) 2024-09-30
SG11201407337QA (en) 2014-12-30
AU2018200444B2 (en) 2019-10-31
CL2014003055A1 (es) 2015-02-13
EA033614B1 (ru) 2019-11-11
KR20190137963A (ko) 2019-12-11
KR20240119191A (ko) 2024-08-06
LT2662094T (lt) 2024-07-10
KR20200130748A (ko) 2020-11-19
US10159746B2 (en) 2018-12-25
AU2013259573B2 (en) 2018-02-15
FI2662094T3 (fi) 2024-06-26
EP2662094B1 (en) 2024-04-17
MX2019004845A (es) 2021-03-31
WO2013169897A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
HK1250927A1 (zh) 用於配製肽蛋白酶體抑制劑的環糊精絡合法
ZA201207384B (en) Cylodextrin complexation methods for furmulating peptide proteasome inhibitors
EP2755192A4 (en) VISUALALLY DISTANCE DRIVING DETECTION DEVICE
SI2753334T1 (sl) Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev
EP2872976A4 (en) APPARATUS FOR DETECTING
EP2687055A4 (en) ENHANCED DETECTION OF THE POSITION OF A DEVICE
EP2877457A4 (en) CYSTATHIONINE -LYASE INHIBITORS (CSE)
EP2877458A4 (en) CYSTATHIONINE-Y-GAMMA-LYASE (CSE) -HEMMER
EP2685271A4 (en) MAGNETIC DETECTION DEVICE
EP2785183A4 (en) TRIAZOLOPYRIDINONE PDE10 INHIBITORS
EP2725338A4 (en) TIRE TEST DEVICE
EP2787496A4 (en) OBJECT DETECTION DEVICE
GB2502243B (en) Ion detection
GB2494284B (en) Detection aid device
EP2772636A4 (en) DEVICE FOR DETECTING CATALYST DEGRADATION
GB2492805B (en) Apparatus for measuring an article
EP2755184A4 (en) OBJECT DETECTION DEVICE
ZA201300859B (en) Sweep design for seismic sources
GB2490789B (en) A device for withdrawing objects from a narrow space
EP2661633A4 (en) PROOF OF PROTEOLYSIS
HK1209422A1 (zh) 抑制劑
GB2495391B (en) Detection device
HK1212997A1 (zh) 酮酰胺免疫蛋白酶體抑制劑
EP2888538C0 (de) Vorrichtung für die befestigung von gegenständen
IL220947A (en) Ablator test facility